Exploring Analyst Estimates for Novartis (NVS) Q1 Earnings, Beyond Revenue and EPS
Evaluate the expected performance of Novartis (NVS) for the quarter ended March 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics...
Novartis (NVS) Presents Positive Data on Rare Kidney Disease Drug
Novartis (NVS) announces encouraging data on Fabhalta from a phase III study for the treatment for the treatment of immunoglobulin A nephropathy, a heterogeneous, progressive, rare kidney disease.
Novartis (NVS) Inks Deal for ARVN's Prostate Cancer Candidate
Novartis (NVS) enters into a license deal with Arvinas, Inc. (ARVN) for the worldwide development and commercialization of cancer candidate ARV-766. Shares of ARVN rise on the news.
Novartis (NVS) to Undertake Job Cuts in Development Department
Novartis (NVS) is set to cut jobs by 680 in its development organization to reshape workforce.
Novartis Layoffs 2024: What to Know About the Latest NVS Job Cuts
Novartis (NYSE: NVS ) layoffs are in the news Wednesday after the healthcare company announced plans to cut jobs in the U.S. and Switzerland. Starting with its U.S. jobs, the company intends to red...
Novartis to cut 680 jobs in product development
Novartis is to cut up to 680 jobs in its development organisation, which helps bring its drugs to market, the Swiss pharmaceuticals company said on Tuesday.
Novartis To Seek Label Expansion of Prostate Cancer Treatment After Successful Study
Shares of Novartis (NVS) climbed Thursday as the pharmaceutical firm announced it would seek approval for expanded use of its cancer treatment, Pluvicto.
Novartis: Higher Guidance, Now A Buy
Novartis is now a pure player in innovative medicines. Despite a negative FX, the company reported solid 2023 financial results and increased its dividend per share. There is a strategic rationale ...
Investors Heavily Search Novartis AG (NVS): Here is What You Need to Know
Zacks.com users have recently been watching Novartis (NVS) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Novartis (NVS) Increases Yet Falls Behind Market: What Investors Need to Know
Novartis (NVS) closed at $95.88 in the latest trading session, marking a +0.64% move from the prior day.
Novartis (NVS) Declines More Than Market: Some Information for Investors
In the most recent trading session, Novartis (NVS) closed at $95.73, indicating a -0.52% shift from the previous trading day.
1 Magnificent Dividend Stock to Buy and Hold
Novartis is an innovative drugmaker that delivers strong financial results. The Swiss pharmaceutical giant's dividend history is also impressive.
US appeals court revives Regeneron's antitrust lawsuit against Novartis
A U.S. appeals court on Monday revived an antitrust lawsuit by Regeneron Pharmaceuticals against Novartis related to prescription treatments to address a condition that can lead to eye disorders in...
Novartis (NVS) Stock Dips While Market Gains: Key Facts
In the most recent trading session, Novartis (NVS) closed at $99.77, indicating a -1.58% shift from the previous trading day.
Novartis (NVS) Advances While Market Declines: Some Information for Investors
Novartis (NVS) closed the most recent trading day at $101.37, moving +0.66% from the previous trading session.
Related Companies